Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024
Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.
Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024
Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC
Webinar to be held on Friday, October 27, 2023 from 12:30 pm - 1:45 pm Eastern Time
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®
Genprex's Chief Financial Officer, Ryan Confer, shares his insight on partnering with academic institutions, the benefits, and best practices
Diabetes is the most expensive chronic illness in the U.S., with $1 of every $4 in healthcare costs going to care for diabetics. The National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) estimates that $237 billion is spent directly on diabetes-related medical costs every year, while another $90 billion is lost each year due to reduced productivity associated with diabetes.
Designed and Secured by Barsec